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Attainment of appropriate pharmacokinetic-pharmacodynamic (PK-PD) targets for antimicrobial treatment is 32 
challenging in critically ill patients, particularly for cefepime, which exhibits a relative narrow therapeutic-toxic 33 
window compared to other beta-lactam antibiotics. Target Controlled Infusion (TCI) systems, which deliver 34 
drugs to achieve specific target drug concentrations, have successfully been implemented for improved dosing of 35 
sedatives and analgesics in anesthesia. We conducted a clinical trial in the Intensive Care Unit (ICU) to 36 
investigate the performance of TCI for adequate target attainment of cefepime. Twenty-one patients treated per 37 
standard of care with cefepime were included. Cefepime was administered through continuous infusion using 38 
TCI for a median duration of 4.5 days. TCI was based on a previously developed population PK model 39 
incorporating the estimated creatinine clearance based on the Cockcroft-Gault formula as input variable to 40 
calculate cefepime clearance. A cefepime blood  concentration of 16 mg/L was targeted. To evaluate the 41 
measured versus predicted plasma concentrations, blood samples were taken (median of 10 samples per patient) 42 
and total cefepime concentrations were measured using UPLC-MS/MS. Performance of the TCI system was 43 
evaluated using the Varvel criteria. Half (50.3%) of measured cefepime concentrations were within ± 30% 44 
around the target value of 16 mg L-1. The wobble was 11.4%, median prediction error (MdPE) was 21.1%, 45 
median absolute prediction error (MdAPE) was 32.0%, and divergence was -3.72%.h-1. Based on these results 46 
we conclude that TCI is useful for dose optimization of cefepime in ICU patients. 47 
 48 

























Inappropriate dosing of antibiotics is a driver for antimicrobial resistance development (1), acute 61 
toxicity (2,3) and poor clinical outcome (4-5). This is particularly true for cefepime, a fourth generation 62 
cephalosporin, which has shown to exhibit a narrow therapeutic-toxic window (2-3,6). Defining adequate dosing 63 
regimens in critically ill patients is challenging as pharmacokinetics (PK) in these patients are known to vary 64 
considerably (7-14) and these patients are more likely to be infected by less susceptible bacteria (12).       65 
Traditionally, dosing of antibiotics is based on nomograms which define a dosing regimen based on one 66 
or a limited set of patient covariates. In the critically ill, these nomogram-based dosing regimens frequently 67 
result in a significant proportion of patients not achieving the therapeutic target (13). Hence, treatment should be 68 
individualized using therapeutic drug monitoring and/or population PK (PopPK) models. In recent years several 69 
software packages were developed that allow model-based treatment individualization (14). Whilst therapeutic 70 
drug monitoring (TDM) linked with Bayesian forecasting provides a powerful opportunity for delivering 71 
individualized care for patients (15), several issues in current strategies for dose optimization of antimicrobials 72 
have hindered clinical implementation in most ICU’s (16,17).  73 
Target-controlled infusion (TCI) is a technique of continuously infusing intravenous drugs and is 74 
mainly known in the field of anesthetics (18). TCI allows the clinician to target a predefined concentration in a 75 
specific body compartment or tissue of interest. The computer then calculates the optimal infusion rate required 76 
to achieve this user-defined target concentration as fast as possible without overshooting the target, based on a 77 
PopPK model and patient specific covariates (e.g. age, weight, serum creatinine, etc.) which are integrated in the 78 
model. An on-line coupled infusion pump then delivers this optimal infusion regimen to the patient. In 79 
comparison to the aforementioned manually controlled infusions, TCI systems might provide a more convenient 80 
and performant alternative. Treatment individualization is made easy as the PopPK model and associated 81 
covariates are embedded in the TCI devices. Dose adaptations are not limited to practicable changes in infusion 82 
rates, dose strengths, dosing intervals, etc. but TCI continuously calculates and adjust the infusion rate to exactly 83 
match the distribution and elimination kinetics of the drug during treatment.  84 
In this prospective pharmacokinetic study, we evaluated the performance of  a cefepime TCI system in a 85 
cohort of critically ill patients. Furthermore, the additional PK data was used to update the earlier presented 86 
















Twenty-one critically ill patients were included in this study. Patients received cefepime for the 90 
following indications: suspected or documented respiratory infection (18 of 21; 86%), abdominal infection (1 of 91 
21; 5%), combined respiratory and abdominal infection (1 of 21; 5%) or infection of unknown origin (1 of 21; 92 
5%). Microbiological samples taken before cefepime treatment identified in 16 of 21 (76%) patients one or more 93 
pathogens: Klebsiella spp. (n = 8), Escherichia coli (n = 6), Citrobacter spp. (n = 2), Proteus mirabilis (n = 1), 94 
Pseudomonas aeruginosa (n = 1), Morganella morganii (n = 1) and Enterobacter cloacae (n = 1), 95 
Staphylococcus aureus (n = 1) and Haemophilus influenzae (n = 1). MIC values for cefepime ranged from ≤ 1 96 
mg L-1 to 4 mg L-1 (75th percentile: ≤ 1 mg L-1). Table 1 shows a the clinical characteristics of the study patients. 97 
The median treatment duration with TCI was 4.0 days (IQR: 2.0 – 5.0 days) and daily cefepime dose 98 
was 1.8 g (IQR: 1.6 – 2.5 g) at day 1, 1.3 g (IQR: 1.1 – 2.2 g) at day 2, 1.3 g (IQR: 1.1 – 2.0 g) at day 3 and 1.3 g 99 
(IQR: 1.1 – 1.9 g) at day 4. During treatment, a median of 10 blood samples were taken per patient (IQR: 9 – 11) 100 
leading to a total of 201 samples.  The median of the measured cefepime plasma concentrations was 19.2 mg L-1 101 
with an inter-quartile range of 15.3 to 23.3 mg L-1 (the mean and SD were 19.5 and 6.36 mg L-1, respectively). 102 
The percentage of measured concentrations within ±10, 20, 30, 40 and 50% of the 16 mg L-1 target were 20.7, 103 
36.2, 50.3, 66.3 and 77.7%, respectively.  Figure 1 shows the measured cefepime concentrations and the 104 
predicted concentrations according to the TCI system. The average performance metrics (Varvel criteria) in this 105 
patient cohort were: MdAPE: 28.7 %, MdPE: 20.3 %, Wobble: 12.2 %, Divergence: -0.13 % h-1. As seen from 106 
Figure 1 performance varies with MdAPEs on an individual basis ranging between 4.1% and 64.2%. Similar 107 
variability was found for the other performance metrics; MdPE (range): -25.6% to 64.2%, Wobble (range): 2.12 108 
% to 30.3 % and Divergence (range): -4.43 % h-1 to 0.68 % h-1. 109 
By combining the data from this study with the study previously published by our group (19), we were 110 
able to improve the PopPK model for cefepime. The following modifications led to a significant improvement in 111 
the goodness-of-fit: (i) the implementation of eCrCL as time-varying covariate on CLrenal, (ΔOFV: -75.3) and (ii) 112 
the addition of between-subject variability (BSV) on the non-renal CL (CLother) (ΔOFV: -54.0). Finally, we made 113 
two modifications that slightly worsened goodness-of-fit: a power parameterization for the eCrCL effect on CL 114 
instead of the original linear relationship (ΔOFV: +2.2) and scaling of all PK parameters with body weight 115 
according to allometric theory (ΔOFV: +2.3) (20). The former was added to the model to avoid the prediction of 116 
negative CLrenal at very low eCrCL values whereas the latter was included to ascertain sensible behavior of a TCI 117 
system based on this model when used in patients with a bodyweight outside the range evaluated in this analysis 118 
(50 - 120 kg). None of the other covariates tested in the model (age, plasma albumin levels and C-reactive 119 
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protein (CRP)) were found significant. Parameter estimates and associated relative standard errors for the final 120 
model are shown in Table 2.  The covariate structure for the final model (for a non-dialysis patient) is shown in 121 
equations 1-4. Goodness-of-fit plots for the final PopPK model are provided as supplemental material (Fig. S1). 122 










 Eq.1 123 
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In this study we describe for the first time the use of TCI for the administration of antibiotics in 130 
critically ill patients. PK-PD optimized dosing regimens and target attainment are pivotal for effective 131 
antimicrobial treatment (4-5). As a result, different approaches to personalized antibiotic dosing have been 132 
attempted (15,21-24). TCI systems accomplish this individualization via embedded PopPK models and might 133 
therefore become a convenient bedside alternative to other approaches. Our prototype TCI system delivers 134 
50.3% of measured cefepime concentrations within ± 30% around the target value of 16 mg L-1. MdPE and 135 
MdAPE in this study were 20.3 % and 28.7 %, respectively. This performance is in line with the performance of 136 
current PK models used in TCI pumps in anaesthesia (25). 137 
Cefepime was selected as study drug because it is widely used as broad spectrum antibiotic in ICU 138 
patients and individualized TCI dosing has a potential benefit given the relatively small therapeutic-toxic 139 
window, compared to other beta-lactam antibiotics. It is important to note that there exist no clinically validated 140 
target cefepime concentration for continuous infusion. We choose a target (total) cefepime concentration of 16 141 
mg L-1 for all patients in our study, which is a compromise between potential toxicity and achieving adequate 142 
PKPD targets. The chosen target concentration is well below the recently advocated threshold for cefepime 143 
toxicity of 35 mg L-1 (6) and is sufficient to achieve free drug above the EUCAST clinical susceptibility 144 
breakpoint for the suspected pathogens (e.g. MIC = 1 mg L-1 for Enterobacterales and MIC = 8 mg L-1 for 145 
Pseudomonas spp.) (http://www.eucast.org). The target resembles the clinical use of cefepime when 146 
microbiology results are absent, such as e.g. when used empirically or when cultures remain negative throughout 147 
the treatment period (26,27). In these situations population-level assumptions are made about the most likely 148 
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organism causing the infection and the distribution of MICs in this population. To achieve true individualization 149 
of antibiotic therapy, it might also be necessary to individualize the targeted PKPD index (i.e. more aggressive 150 
PKPD targets such as fT>2.1xMIC (28) or T>4.3xMIC (29)) and to account for the susceptibility of the infecting 151 
pathogen (once isolated). TCI systems facilitate the use of a patient-tailored target by reducing the complex 152 
dose-concentration relationship via the embedded PopPK models to the selection of an appropriate plasma 153 
concentration target. In our opinion, this practicable flexibility could drive the wide-spread implementation of 154 
model-informed precision dosing for antibiotics in the ICU. The use of TCI is not limited to cefepime, but the 155 
concept could also be applied to administer any drug that can be give as continuous infusion. 156 
 The additional PK data from this study enabled us to update the PopPK model used in our prototype 157 
TCI system. From the pooled data analysis V1 was estimated to be 10.7 L and not 18.3 L, as published earlier by 158 
our group (19). As a result, loading doses administered by the current version of the TCI system are too high, 159 
resulting in an overshoot of the target in the first hour of treatment (as seen from Figure 1). Furthermore, our 160 
analysis indicated that within-individual changes in cefepime clearance are (partly) explained by temporal 161 
changes in eCrCL. We hypothesize that an updated version of the TCI system based on the new PopPK model 162 
and with eCrCL as a control variable to accommodate within-subject variability in CL will perform better than 163 
the system evaluated in this study.  164 
The theoretical lower limit for the performance of this new system depends on the magnitude of the 165 
unknown BSV in the PopPK model. When targeting a steady-state plasma concentration and assuming that the 166 
PopPK model in the TCI system is unbiased, target attainment is limited by the BSV in CL. In our model CL 167 
consists of CLrenal with a BSV of 24.6% and CLother with a BSV of 69.4%. Consequently, when targeting 16 mg 168 
L-1 95% of patients are expected to reach a steady-state concentration between 9.16 and 24.6 mg L-1 (based on 169 
simulations for a population with an average eCrCL of 60 mL min-1). This translates to a MdAPE of 21.5%, 170 
which is, as expected, lower than the MdAPE reported in this study (28.7%). This shows that it is possible to 171 
improve the performance of the current TCI system by updating the embedded PopPK model.  172 
Another useful approach for further refining the accuracy of the system is to use model-based feedback-173 
control based on Bayesian forecasting of PK parameters . Open-loop TCI systems (or adaptive TCI systems) (30) 174 
where feedback from TDM is used as a control variable in the TCI system are interesting in that respect.  Neely 175 
et al. (21), Matthews et al. (23) and Pea et al. (24) have shown for aminoglycosides and vancomycin that TDM 176 
and Bayesian forecasting of PK parameters results in improved dosing accuracy over conventional dosing 177 
strategies. Hence, a TCI system based on the same principles might be advantageous when a higher accuracy is 178 
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needed. The lower limit for the performance of such a system is not depending on the BSV in the PK but is 179 
governed by the residual variability of the PopPK model, which incorporates both the inaccuracy in the drug 180 
assay and model misspecification. For the updated model this would result in a MdAPE of 12.8%. Nevertheless, 181 
timely availability of appropriate antimicrobial assays could be problematic as TDM programs for cefepime or 182 
other beta-lactam antibiotics are not yet widespread. To this end, biosensor technology could offer an alternative 183 
by providing real-time monitoring of antimicrobials in a minimally invasive fashion (31). 184 
 185 
There are some limitations to the research presented here: firstly, the small number of patients examined 186 
and the fact that all patients originate from only one ICU site. Although patient inclusion was not restricted to 187 
any medical condition and all patients receiving cefepime with a eGFR > 15 mL/min were eligible, extrapolation 188 
of the results to specific subgroup of patients may not be appropriate. For instance, only few patients with 189 
augmented renal clearance were included. Secondly, the model by Jonckheere et al. (19) uses only eCrCL to 190 
individualize cefepime dosing. A more sophisticated PopPK model, also including patient covariates on the 191 
volume of distribution, would have likely resulted in better treatment individualization and potentially better 192 
performance.  Finally, the TCI performance might be overestimated because the PopPK model which was 193 
integrated in the TCI was developed in the same ICU. 194 
In conclusion, novel systems are urgently required to individualize antimicrobial therapy, to address the 195 
wide variations in PK currently observed across a range of patient populations, and to minimize the occurrence 196 
of sub-optimal dosing. We demonstrated that cefepime TCI is able to deliver antibiotic concentrations within the 197 
expected range around the targeted plasma concentrations in a cohort of critically ill ICU patients. In our 198 
opinion, TCI offers exciting possibilities for the individualization of antibiotic treatment in ICU patients and 199 
could drive the wide-spread implementation of model-informed precision dosing in this vulnerable patient 200 
population. Further research is needed to confirm that target attainment is superior and to demonstrate increased 201 




















MATERIALS AND METHODS 209 
Patient inclusion & research ethics. Patients requiring cefepime according to local treatment protocols 210 
were included between May 2016 and August 2017. Patients with an estimated glomerular filtration rate (eGFR) 211 
(according to CKD-EPI formula) less than 15 mL/min and patients that were on hemodialysis were excluded. 212 
This trial was conducted at the Intensive Care department of the OLV Hospital Aalst, Belgium, in accordance 213 
with the Declaration of Helsinki and in compliance with Good Clinical Practice and the applicable regulatory 214 
requirements. Ethical approval was obtained from the Institution Review Board of the hospital (Belgium 215 
registration number: B126201626975). The study was registered in the ClinicalTrials.gov database 216 
(NCT02688582) and was monitored by an independent Quality Specialist. 217 
Drug administration. Patients received cefepime i.v. using a TCI system based on a previously 218 
developed PopPK model by Jonckheere et al. (19). In this model, the estimated creatinine clearance (eCrCl) 219 
based on the Cockcroft-Gault formula measured the day of inclusion was used as only input variable and a 220 
cefepime blood concentration of 16 mg/L was targeted. There were no adaptations based on changes in eCrCl or 221 
measured cefepime concentrations during treatment. Cefepime (20 mg/mL, Fresenius Kabi®, USA) was 222 
administered by a syringe pump (Orchestra® Module DPS, Fresenius Kabi®, USA) controlled by RUGLOOPII 223 
software (Demed®, Temse, Belgium) on a personal computer. Maximum infusion rate was set to 4 gram of 224 
cefepime per hour. 225 
Descriptive statistics. The administered daily cefepime dose was extracted from the case report forms 226 
or the RUGLOOPII files. CRP measurements were summarized according to 24h intervals. Measurements up to 227 
24h before inclusion into the study were grouped as baseline measurements. Daily doses of cefepime and CRP 228 
levels were analysed for the first 4 days of therapy only, afterwards the number of patients treated was too low to 229 
calculate meaningful summary measures. Length-of-stay in ICU/Hospital and mortality are competing risks (i.e. 230 
very sick patients who die would have likely had a very long stay in ICU/Hospital), hence the length-of-stay was 231 
calculated by replacing length-of-stay for patients who died by the maximum length-of-stay in that patient cohort 232 
(32). Presence of neurotoxicity was based on clinical assessment. 233 
Arterial blood and urine sampling and laboratory procedures. Arterial blood was sampled at 0.5, 1, 234 
3, 6, 12, 24, 36, 48, 72, 96 and 120 h after the start of the infusion. The exact timing of blood samples was 235 
recorded in the case report form. Samples were collected in lithium heparin tubes, transported immediately to the 236 
laboratory and centrifuged at 1000 xg for 5 min at 4°C. Subsequently, plasma samples were stored below -70°C 237 
until analysis. Urine was collected daily from a urinary catheter over a 12 hour interval. The quantification of 238 
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cefepime levels was based on a validated solid phase extraction – liquid chromatography electrospray – tandem 239 
mass spectrometry method (33). using a 13C12-
2H3-labeled cefepime isotope as internal standard (AlsaChim, 240 
Illkirch, France). The range of the analytical method was 0.15 mg L-1 to 15 mg L-1 with an average bias and 241 
imprecision of +5.9 % and 8.6 CV%. Plasma samples were diluted 1/5 in blank human plasma whereas urine 242 
samples were diluted 1/50 in blank human plasma prior to analysis. All samples were measured in duplicate. 243 
Microbiological samples were taken as per standard of care and analyzed using standard culture procedures. 244 
Identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 245 
(MALDI-TOF MS) (Bruker Daltonik GmbH, Germany) and antimicrobial susceptibility testing was performed 246 
using the Phoenix system (Becton Dickinson, USA) according manufacturer’s instructions. 247 
Calculation of predictive performance. In line with studies on the performance of TCI systems in 248 
anesthesia, we used the “Varvel criteria” to evaluate the performance of our TCI system (34). For this, the 249 
performance error (PE) is calculated for all samples (j) for the different patients (i) according to equation 5. 250 




 x 100%  Eq 5. 252 
 253 
In this equation Cmeas ij and Cpred ij are the measured and predicted plasma cefepime concentrations, respectively.  254 
Subsequently, the PEs are used to calculate the median PE (MDPE), median absolute PE (MDAPE), wobble, and 255 
divergence for each patient. MDPE provides a measure of bias whereas the MDAPE reflects the precision of the 256 
system. Wobble is a measure of intra-subject variation in PEs and the divergence quantifies any time-related 257 
changes in the imprecision of the TCI system.  258 
Update of previously published population pharmacokinetic model. The plasma and urine cefepime 259 
concentration versus time data were fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; 260 
GloboMax LLC, Hanover, MD, USA). The “tidyverse” package (Version 1.1.1.; Wickham H. 2017) in R® (R 261 
foundation for statistical computing, Vienna, Austria) was used to graphically assess the goodness-of-fit. As a 262 
starting point, the model previously published by our group (19), which was used as PopPK model in the 263 
presented TCI system, was fitted to the combined dataset (PK data from the pilot study (19) and additional PK 264 
data from this TCI study). Modifications to the model were accepted if they resulted in a decrease in the 265 
objective function value (OFV). A decrease in OFV was judged statistically significant if inclusion of an 266 
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FIGURE LEGENDS 416 
FIG 1 Measured cefepime concentrations (black dots) with non-parametric smoother (blue line) and target 417 
window of 16 mg/L  of the 21 included patients. Black line represents expected plasma concentrations based on 418 
TCI model. Median absolute prediction error (MdAPE) is presented for each patient. 419 
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Table 1 Clinical characteristics of study patients (n=21). 
Clinical outcome n (%) or median (IQR) 
Age 76 (72 – 78) 
Male/female 16 (76) / 5 (24) 
Body weight (kg) 76 (67 – 86) 
BMI (kg/m2) 26.3 (23.5 – 27.8) 
Body surface area (m2) 1.88 (1.77 – 2.03) 
SOFA score at inclusion 7 (3 - 8) 
Patients on mechanical ventilation at inclusion 7 (33) 
Serum creatinine (mg/dL) 1.49 (0.66 – 2.14) 
Cockcroft-Gault (mL/min) 50.4 (29.1 – 100) 
MDRD (mL/min/1.73 m2) 42.3 (30.1 – 106) 
CKD-EPI (mL/min/1.73 m2) 38.8 (26.8 – 83.3) 
CRP (mg L-1)  
   At study inclusion  197 (95.7 – 287) 
   0 – 24 h  189 (115 – 282) 
   24 – 48 h  133 (92.6 - 195) 
   48 – 72 h 89.2 (62.5 - 122) 
   72 – 96 h 69.0 (46.7 – 88) 
Length of stay in ICU (days)a    7 (5 – 10) 
Length of stay in hospital (days)a 21 (13 – 28) 
In hospital mortality 5 (24) 
Event of neurotoxicity 0 (0) 
a mortality-corrected length of stay 
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Table 2 Parameter estimates and associated relative standard errors (RSE%) for the final population PK model derived from 
simultaneously fitting the data from our previous study (19) (STDY1) and the data from this study (STDY2). Between-
subject variability associated with the typical parameters is expressed as CV%. eCrCL was according to Cockcroft-Gault and 
was interpolated using constant backward interpolation.  
 PK Parameter Estimate (RSE%) 
CLrenal (L h
-1 70 kg-1) � ∙ ����� � ∙ � −6 �2 
θ1 2.29 (5.4) 
θ2 0.943 (9.6) 
CLother (L h
-1 70 kg-1) 
0.795 (9.0) 
V1 (L 70 kg-1) 
10.7 (8.1) 
V2 (L 70 kg-1) 
12.2 (7.2) 





Between-subject variability (CV%a) 
 
CLrenal  24.6 (28) 
V1 
45.7 (31) 
CLother 69.4 (32) 
Residual  unexplained variability (CV%) 
 
PlasmaSTDY1 31.8 (17) 
PlasmaSTDY2 12.8 (25) 
UrineSTDY1 32.5 (27) 
UrineSTDY2 33.3 (42) 
V1, volume of distribution of the central compartment; V2, volume of distribution of the peripheral compartment; Q2, inter-compartmental 
clearance between V1 and V2; CLrenal, renal clearance; CLdialysis, clearance during intermittent haemodialysis; CLother, non-renal 
clearance. Separate clearance terms are integrated in the model describing renal clearance, non-renal clearance and clearance during 
haemodialysis. For patients on IHD, we assumed that renal clearance was absent. 
a CV (%) is calculated according to: √� ∗ % where ω² is the estimated variance in NONMEM 
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